Lunai Bioworks Inc.

LNAI Nasdaq CIK: 0001527728

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES, CA, 90067
Mailing Address CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES, CA, 90067
Phone 45 39179840
Fiscal Year End 0630
EIN 452259340

Financial Overview

FY2025

$-0.91
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events February 12, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment December 9, 2025 View on SEC
8-K Current report of material events December 3, 2025 View on SEC
424B5 Prospectus supplement December 3, 2025 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment November 28, 2025 View on SEC
8-K Current report of material events November 25, 2025 View on SEC
10-Q Quarterly financial report November 14, 2025 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment November 12, 2025 View on SEC
8-K Current report of material events November 6, 2025 View on SEC
8-K Current report of material events November 3, 2025 View on SEC

Annual Reports

10-K September 29, 2025
  • FDA approved early testing for their cancer drug (pre-clinical phase, 5+ years from market)
  • Acquired AI drug-discovery startup Biosymetrics for $6M in stock
View Analysis

Material Events

8-K Financial Distress February 12, 2026
High Impact
  • Lunai Bioworks Inc. received a Nasdaq delisting notice due to its stock price falling below the $1.00 minimum bid requirement.
  • The company does not qualify for the standard 180-day grace period because it executed a 1-for-10 reverse stock split on September 30, 2025.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.